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Background: Temozolomide (TMZ) is the most widely used drug to treat glioblastoma (GBM), which is the most
common and aggressive primary tumor of the Central Nervous System and one of the hardest challenges in
oncotherapy. TMZ is an alkylating agent that induces autophagy, apoptosis and senescence in GBM cells. However,
therapy with TMZ increases survival after diagnosis only from 12 to 14.4 months, making the development of
combined therapies to treat GBM fundamental. One candidate for GBM therapy is Resveratrol (Rsv), which has
additive toxicity with TMZ in several glioma cells in vitro and in vivo. However, the mechanism of Rsv and TMZ
additive toxicity, which is the aim of the present work, is not clear, especially concerning cell cycle dynamics and
long term effects.
Methods: Glioma cell lines were treated with Rsv and TMZ, alone or in combinations, and the induction and the
role of autophagy, apoptosis, cell cycle dynamics, protein expression and phosphorylation status were measured.
We further evaluated the long term senescence induction and clonogenic capacity.
Results: As expected, temozolomide caused a G2 cell cycle arrest and extensive DNA damage response. Rsv did
not reduced this response, even increasing pATM, pChk2 and gammaH2Ax levels, but abrogated the
temozolomide-induced G2 arrest, increasing levels of cyclin B and pRb(S807/811) and reducing levels of pWee1
(S642) and pCdk1(Y15). This suggests a cellular state of forced passage through G2 checkpoint despite large DNA
damage, a scenario that may produce mitotic catastrophe. Indeed, the proportion of cells with high nuclear
irregularity increased from 6 to 26% in 48 h after cotreatment. At a long term, a reduction in clonogenic capacity
was observed, accompanied by a large induction of senescence.
Conclusion: The presence of Rsv forces cells treated with TMZ through mitosis leading to mitotic catastrophe and
senescence, reducing the clonogenic capacity of glioma cells and increasing the chronic effects of temozolomide.
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More than 20,000 cases of malignant tumors of the Central
Nervous System are diagnosed every year in the United
States [www.cbtrus.org] [1]. Of these, more than half are
Glioblastomas (GBM), which is the most malignant
subtype and are normally treated with surgery, followed
by radiotherapy and chemotherapy with Temozolomide
(TMZ) [2,3]. However, TMZ therapy produces only modest
increase in survival, maintaining GBM as a cancer with a
median survival of about one year after diagnosis and caus-
ing over 10,000 deaths per year only in the USA. Therefore,
treatment of GBM remains one of the hardest challenges
to be tackled by oncotherapy [4].
TMZ is a cytotoxic imidazotetrazine that leads to the
formation of O6-methylguanine, which mismatches with
thymine in subsequent DNA replication cycles. This was
described as leading to several cellular outcomes, such
as apoptosis [5,6], autophagy [7], mitotic catastrophe
and senescence-like events [5] in GBMs. In most cells,
TMZ produces cell cycle arrest at G2/M through
activation of ATM/ATR-Chk1/2 [8]. Chk1/2 can activate
Wee1, the kinase that phosphorylates Cdk1 at the inhibi-
tory tyrosine 15 site, whereas it can inhibit CDC25A, the
phosphatase responsible for dephosphorylating this site
[9], thus leading to an arrest before mitosis. Activation
of G2 checkpoint acts primarily as a prosurvival mech-
anism that gives time to the cells to repair their DNA.
Impeding the cell cycle arrest in DNA-damaged cells
normally leads to cell death by mitotic catastrophe (MC)
[5], a failure caused by mitosis entry even in the pres-
ence of DNA damage or checkpoint activation [10,11].
Some cancer types, such as GBM, are intrinsically resist-
ant to apoptosis and may be more sensitive to other
mechanisms of cell death, such as autophagy, senescence
and MC [12,13].
Resveratrol (Rsv) has several beneficial properties in
age-associated chronic diseases, diabetes and cardiovas-
cular diseases [14] and is neuroprotective in neurological
conditions such as ischemia and hypoxia [15]. On the
other hand, Rsv is cytotoxic to several types of malignant
cells, such as colon cancer [16], breast cancer [17], mela-
nomas [18], leukemia [19] and prostate cancer [20]. In
GBM, it inhibits cell growth and causes cell death
through mechanisms that include autophagy [21,22],
apoptosis [23] and senescence [24]. Rsv exerts its cyto-
toxic and cytostatic effects through specific cell cycle
modulation in several cancer types, including S-phase
arrest in ovarian cancer [25] and medulloblastoma cells
[26], G1 arrest in prostate cancer [27] and melanoma
[28] and S/G2 arrest in leukemia cells [29].
Rsv was described to act synergistically with TMZ on
apoptosis, accompanied by a decrease of TMZ-induced
cytoprotective autophagy and a decrease of reactive oxy-
gen species (ROS). This effect was mimicked by theantioxidants vitamin C and tiron, suggesting an effect
mediated primarily by ROS [30]. Yuan et al. showed, in
turn, that Rsv increased the TMZ-induced G2 cell cycle
arrest in SHG44 glioma cells, accompanied by an in-
crease in ROS production, leading to AMPK activation
and mTOR inhibition, triggering apoptosis through the
reduction of the antiapoptotic protein Bcl-2 [31]. How-
ever, the mechanism of action of the cotreatment is far
from clear, and important mechanisms, such as cell cycle
dynamics and long term effects of cotreatment in vitro
were not evaluated, which may be fundamental to plan
in vivo strategies.
Here we show that Rsv potentiates the cytotoxic effect
of TMZ in human GBM cells by increasing DNA dam-
age response (DDR) while blocking the TMZ-induced
cell cycle arrest leading to MC and, in the long term, to
senescence and reduction in clonogenic survival.Methods
Reagents
TMZ (3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-
tetrazine- 8-carboxamide), Rsv, 3-methyladenine (3MA)
and the fluorescent dye acridine orange (AO) were pur-
chased from Sigma-Aldrich Chemical Co. (St. Louis,
MO, USA). TMZ and Rsv were dissolved in dimethyl
sulfoxide (DMSO) (Acros Organics, NJ, USA). 3MA and
AO were dissolved in water. All culture materials were
obtained from Gibco Laboratories (Grand Island, NY,
USA).Cell culture and treatments
Human GBM cell lines U87-MG (p53wt, PTENmut,
p14ARF/p16del, low MGMT levels), U-138 MG (p53mut,
PTENmut, p14ARF/p16del, high MGMT levels) and U251
(p53wt, PTENnull, p14ARF/p16del, low MGMT levels),
described hereafter only as U87, U138 and U251, were
obtained from American Tissue Culture Collection
(ATCC, Rockville, MD). Cell lines were cultured in
DMEM low glucose, while primary cultures were main-
tained in DMEM high glucose, both supplemented with
10% fetal bovine serum (FBS), 1% penicillin/strepto-
mycin and 0.1% amphotericin B at 37°C and 5% CO2 in
a humidified incubator. The inhibitor 3-MA was used at
he concentration of 2 mM, in a pre-incubation of 1 h
before the treatments with Rsv and TMZ. The concen-
tration of the vehicle DMSO did not exceed 0.5%
(v/v). Cells were counted in a hemocytometer and viabil-
ity was accessed by measuring PI incorporation as de-
scribed [32]. Primary GBM culture was established from
a biopsy of a GBM tumor following the ethical proce-
dures approved by the Ethical Committee of PUC-RS
number 07/03562.
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Autophagosome formation: cells were transfected with the
expression vector pEGFP-LC3 (Microtubule-associated
protein 1 light chain 3 (MAP1-LC3), which localizes at the
autophagosome membranes after processing [33]). Cells
were imaged with a Zeiss Axiovert 200, using the 40x ob-
jective and at least 100 green cells per treatment were
counted and the percentage of cells with at least 5 clear
green dots in the cytosol was determined [34].
Acidic vacuolar organelles (AVOs) quantification: ac-
ridine orange (AO) is a marker of AVOs that fluoresces
green in the whole cell except in acidic compartments
(mainly late autophagosomes), where it fluoresces red.
Cells were plated at 2 × 104 cells per well in a 24-wells
plate, followed by treatments as indicated. After this,
cells were incubated with 2.7 μM of AO for 15 min at
room temperature, followed by visualization in a fluores-
cence microscope. Images were analyzed using Image J
software. To quantify the percentage of cells with AVOs
(i.e. red marked cells) and the intensity of red fluores-
cence (i.e. the intensity of AVOs formation), treated cells
were detached from the plate, marked with AO as cited
above and analyzed by flow cytometry, using a flow
cytometer GUAVA EasyCyte and GUAVA software
ExpressPlus (Guava Technologies, Hayward, CA).
Annexin-V staining
Apoptosis induction was quantified by Annexin V-
FLUOS Apoptosis Kit (Roche, Germany) according to
manufacturer’s instructions with minor modifications, as
described [24].
Cell cycle
For cell cycle analysis, cells were plated at 2 × 104 cells per
well in a 24-wells plate, followed by treatments as indi-
cated. After treatments, cells were harvested and fixed in
ice-cold ethanol 70% (v/v in PBS) for at least 2 h. Fixed
cells were washed with PBS and marked with a solution
containing 50 μg/ml PI, 0.1% Triton X-100 and 50 μg/mL
RNAse for 30 min, in the dark, at room temperature.
Marked cells were analyzed using the flow cytometer
GUAVA EasyCyte software to evaluate DNA content of
cells and, thus, cell cycle distribution of samples.
Comet assay
TMZ, Rsv and cotreatment-induced DNA damage was
quantified using the alkaline comet assay, as described
by Singh et al., with minor modifications [35-37]. Cells
were plated at 5 × 104 cells per well in a 24-wells plate,
followed by treatments for 20 and 48 h, as indicated.
Cells were embedded in 0.75% low-melting agarose and
placed onto a glass microscope slide pre-coated with a
thin layer of 1% normal melting point agarose. Slides
were then incubated in ice-cold lysis solution [2.5 MNaCl, 10 mM Tris, 100 mM EDTA, 1% Triton X-100
and 10% DMSO, pH 10.0] at 4°C for at least 1 h. After,
slides were incubate with fresh alkaline buffer (300 mM
NaOH, 1 mM EDTA, pH. 13.0) and followed by electro-
phoresis. Slides were then neutralized (0.4 M Tris,
pH 7.5), washed with water, and stained using a silver
staining protocol as described by Nadin et al. [38]. One
hundred nuclei were scored blindly according to the
amount of DNA present in the tail and the tail length.
Each nuclei received an arbitrary value range from 0–4
(0, undamaged; 4, maximally damaged) [39], and 100
nuclei per slide were evaluated.Western blot
Analysis of protein expression and phosphorylation was
performed as described previously with minor modifica-
tions [15,24]. Primary antibodies used were: cyclin D1
(1:1000), phospho-Rb (S807/811)(1:1000), phospho-Cdk1
(Tyr15)(1:1000), cyclin B (1:250), phospho-ATM (Ser1981)
(1:1000), phopho-Chk2 (T68)(1:1000), gammaH2AX
(1:1000), phospho-Wee-1 (S642) (1:500) and phospho-H3
(Ser10) (1:1000) (Cell Signal ling, Beverly, MA). Optical
density of the bands was obtained with Bio-Rad software
(Quantity One; Hercules, CA).Clonogenic assay
For clonogenic assay, cells were treated with Rsv, TMZ
or cotreatment for 48 h, followed by medium removal.
Cells were washed twice with PBS, harvested and plated
at a density of 102 cells/well in a 6-wells plate. After
14 days, colonies were fixed with methanol, followed by
staining with 0.1% crystal violet. The number of colonies
was counted and single colonies were photographed for
analysis.SA-beta-gal assay
For senescence measurement, cells were treated with
Rsv, TMZ or cotreatment for 48 h, followed by medium
removal. Cells were washed twice with PBS and replated
at a density of 20 × 103 cells/well, in a 12-wells plate.
After seven days, cells were tested for senescence as de-
scribed [40], with minor modifications. Briefly, cells were
washed with PBS, fixed with 2% paraformaldehyde for
30 min at room temperature and incubated with fresh
SA-beta-gal staining solution (1 mg/mL X-gal (Sigma),
40 mM citric acid/sodium phosphate (pH 6.0), 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide,
150 mM NaCl, and 2 mM MgCl) for 8–12 h at 37°C.
Then, cells were marked with a solution containing 300
nM DAPI and 0.1% triton X-100 (v/v in PBS) for 30 min
at room temperature. Results are presented as ratio of
SA-beta-gal-positive cells to total cells.
Figure 1 Rsv potentiates the cytotoxic effects of TMZ in human
glioma cells. U87 glioma cells were treated with the indicated
doses of Rsv (30 or 100 μM), TMZ or combinations for 48 h, followed
by cell counting; control cells were considered 100%; *p<0.05 and
**p<0.01, in relation to control; a p<0.05 and b p<0.01 in relation to
TMZ and Rsv alone, respectively.
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The analysis of nuclear morphometry was performed
using a tool recently developed by our group [41]. Briefly,
cells were treated as described in SA-beta-gal assay and, at
day 7, cells were fixed with 2% paraformaldehyde (v/v in
PBS) for 30 min at room temperature, and kept in PBS.
Next, fixed cells were marked with a solution containing
300 nM DAPI and 0.1% triton X-100 (v/v in PBS) for
30 min at room temperature, followed by quantification of
the images obtained with DAPI staining using the Soft-
ware Image Pro Plus 6.0 (IPP6 - Media Cybernetics, Silver
Spring, MD) or Image J plugin available at www.ufrgs.br/
labsinal/nma. Data is presented as a plot of Area versus
Nuclear Irregularity Index (NII), which separates nuclei
considering its morphometric phenotype. The percentage
of normal, irregular, large and regular, large and irregular,
small, small and regular and small and irregular nuclei
were determined as described [41].
DCF (dichlorofluorescein) assay
To measure the levels of reactive species, we performed
the DCF assay. The fluorescein derivative DCF (Sigma-
Aldrich) is a non-fluorescent compound which is
converted to a highly fluorescent DCF upon oxidation by
oxygen or nitrogen reactive species. To this, 5 × 104 cells
were plated in 24-well plates, followed by treatments as
indicated. Cells were harvested, washed once with PBS
1× and incubated with 10 μM (in PBS 1×) for 30 min at
37°C prior to analysis by flow cytometry.
Statistical analysis
Statistical analysis was conducted by ANOVA followed by
SNK post-hoc test to multiple comparisons of at least three
independent experiments for all experiments, except when
indicated. ‘p’ value under 0.05 was considered significant.
Analyses were performed using the GraphPadInstat soft-
ware (GraphPad Software, San Diego, CA, USA).
Results
Rsv potentiates the cytotoxic effects of TMZ
TMZ and Rsv individually reduced the number of gli-
oma cells (Figure 1), as shown by others [6,7,24]. When
given together, Rsv potentiated the cytotoxic effect of
TMZ on human glioma cell lines U87, U138 and U251
(Figure 1 and Additional file 1: Figure S1a). A primary
GBM culture which was resistant to TMZ was sensitive
to Rsv and to RT (Additional file 1: Figure S1b). Rsv
30 μM plus TMZ 100 μM (hereafter referred to as RT)
did not induce loss of membrane integrity, large mor-
phological alterations, increase in annexinV/PI-staining or
ROS when cells were treated for 48 h (Additional file 2:
Figure S2), indicating that apoptosis, necrosis or a major
imbalance in ROS levels are not involved in the reduction
in cell number induced by RT.Rsv increases autophagy induced by TMZ, but autophagy
does not affect acute cell death
TMZ, Rsv or RT induced autophagy (Figure 2A,
Additional file 1: Figure S1B and Additional file 3: Figure
S3) both in primary GBM cells and cell lines, which can
be partially inhibited with 3MA, an inhibitor of PI3K
class III, a protein whose activity is necessary for the
early formation of autophagosomes (Figure 2A). RT
induced higher levels of autophagy in an additive man-
ner with respect to Rsv and TMZ alone (Figure 2A,
Additional file 1: Figure S1 and Additional file 3: Figure S3),
however, an efficient inhibition of autophagy with 3MA did
not reduce toxicity of treatments, even increasing the tox-
icity of Rsv, suggesting a small protective role of autophagy
(Figure 2B).
Rsv abrogates TMZ-induced cell cycle arrest
As expected, TMZ induced a robust G2/M cell cycle
arrest in U87 cells, while Rsv did not alter cell cycle dis-
tribution after 48 h of treatment. Interestingly, the pres-
ence of Rsv completely abrogated TMZ-induced cell
cycle arrest (Figure 3A - mid graph). The addition of Rsv
right after a 48 h treatment with TMZ did not alter the
arrest induced by TMZ, suggesting that Rsv inhibits
rather than reverses the cell cycle arrest induced by
TMZ (Figure 3A – right). In U251 cells, Rsv induced a
significant S arrest and slightly reduced TMZ-induced
G2/M arrest, although the effect is less clear due to the
S phase-arrest induced by Rsv. In U138, Rsv induced a
S-phase arrest, but no clear TMZ-induced arrest was ob-
served, which may be due to the high expression of
MGMT (methyl-guanine methyl transferase) in these
cells [42] (Additional file 4: Figure S4).
Since Rsv modulates proteins involved on DNA repair
and interacts directly with DNA in vitro [43], we asked
whether Rsv was abrogating cell cycle arrest due to a
block of TMZ-induced DNA damage or DDR signaling.
Quantification of DNA damage by comet assay indicated
that Rsv did not reduce the TMZ-induced DNA damage
Figure 2 Autophagy is not involved in the toxicity of RT cotreatment. (A) U87 cells were pre-incubated with 3MA (2 mM) or vehicle (PBS)
for 1 h before treatment with Rsv 30 μM, TMZ 100 μM or RT for 48 h. Upper line – LC3-GFP transfected cells; number = percentage of LC3-GFP
-positive cells; scale bar: 10 μm; second line - representative images of AO-marked cells; scale bar: 20 μm; third and fourth lines – flow cytometry of
AO-marked cells; numbers in the quadrants refer to average number of events (black) or mean intensity of red fluorescence (Red) ± SEM;
a p<0.05, b p<0.01 and c p<0.001 in relation to control; d p<0.001 in relation to TMZ alone; * p<0.05 and *** p<0.001 in relation to treatments
with the vehicle; (B) number of cells after pre-treatment with 3MA followed by treatment as in (a); control was considered 100%;
* p>0.05; ** p>0.01, and # p>0.05 in relation to the same treatment without 3MA.
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phorylation levels of H2AX, ATM and Chk2 (Figure 3C).
Actually, RT treatment induced higher levels of gam-
maH2AX, pATM and pChk2 when compared to single
treatments.DDR signals to mitosis by activating Wee1 and
inhibiting CDC25A, which are, respectively, negative
and positive regulators of Cdk1 (Cdc2) [9,44]. Wee1
phosphorylates whereas CDC25 dephosphorylates tyro-
sine 15 of Cdk1, and dephosphorylation of this site is
Figure 3 Rsv abrogates TMZ-induced G2 cell cycle arrest accompanied by decrease of Cdk1(Y15). (A) Cell cycle distribution of U87 cells
treated with Rsv 30 μM, TMZ 100 μM or cotreatment T100+R30 for 48 h (left) TMZ for 72 h, or TMZ 48 h followed by 24 h in complete drug-free
medium, or 24 h of Rsv 30 μM (right). Top: representative histograms of flow cytometry; numbers between the lines indicates the percentage of
cells in each phase of cell cycle, as indicated; a p<0.001 and c p<0.05 in relation to control without drug; (B) DNA damage index measured by
the comet assay in cells treated as in (a) for 20 and 48 h. top panel – representative images of nuclei after comet assay; scale bar: 10 μm;
bottom – quantification of DNA damage index; (C and D) U87 cells were treated with Rsv 30 μM, TMZ 100 μM or cotreatment T100+R30 for 24
or 48 h, followed by western blotting using the indicated antibodies. Numbers indicate the band intensity in relation to control. LC – loading
control (stained membrane); ND – not detected; * p<0.05, ** p<0.01 and *** p<0.001 in relation to control of the same time.
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levels of DDR signaling induced by RT (Figure 3C) does
not translate into increased levels of pWee1, in which
RT-treated cells have a lower level when compared to
Rsv- or TMZ-treated cells, suggesting that Rsv acts as
an inhibitor of the phosphorylation and activation ofWee1, leading to a reduced level of pCdk1 (Y15),
(Figure 3D). Serine 10 of histone H3 is phosphorylated
during mitosis and cells arrested at G2/M by TMZ
showed an increase in the phosphorylation of this site
whereas this was significantly reduced in RT treated
cells. Surprisingly, levels of Cyclin B1, which has to be
Figure 4 (See legend on next page.)
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Figure 4 Inhibition of TMZ-induced G2 arrest by Rsv leads to mitotic catastrophe. U87 cells were treated with Rsv 30 μM, TMZ 100 μM or
RT for 24, 38 and 48 h, followed by fixation and DAPI staining. (A) representative images of nuclei from cells treated with DMSO (control), Rsv for
38 h or RT for 48 h. Double arrows point to fragmented/irregular nuclei; single arrow points to micronuclei; double arrowheads point to enlarged
nuclei; Scale bar: 6 μm; (B) representative visible and fluorescent images of nuclei from untreated cells showing a normal mitosis (i and ii); an
abnormal chromosome condensation and mitosis, with cellular enlargement, in a cell treated with RT for 48 h (iii and iv); and a triple mitosis in
a cell treated with Rsv for 48 h (v and vi) and. Scale bar: 10 μm; (C) direct counting of the percentage of nuclei presenting normal (top), irregular
(mid) or large phenotype (bottom); *p<0.05, **p<0.01 and ***p<0.001 in relation to control; (D) DAPI-stained nuclei were analyzed for size and
irregularity using the NMA tool, as described on material and methods, and the percentage of each nuclear type is shown. At least 200 nuclei in
three independent experiments were analyzed in each data point; *p<0.05 and **p<0.01 in relation to control; #p<0.05 and ##p<0.01 in relation
to TMZ and Rsv alone.
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treated cells (Figure 3D). Noteworthy also is the observa-
tion that phospho(S807/811)-Rb (pRb), which is phos-
phorylated at the G1 to S transition [46] and
dephosphorylated at the completion of M [47], is elevated
with RT (Figure 3D). This reduction of pCdk1 (Y15) to
mitotic permissive levels together with increased levels of
Cyclin B1 leads to a molecular state which can lead to
failed mitosis [48].
RT induces mitotic catastrophe
Cells with DNA damage that bypass cell cycle check-
points tend to undergo MC [10,49]. We observed that
RT-treated cells presented alterations that suggest MC
(Figure 4A and 4B), i.e. aberrant chromosome condensa-
tion and mitotic phenotype, micronuclei and nuclear
fragmentation, and abnormal/triple mitosis.
We developed an objective morphometric analysis of
nuclei size and irregularity [41], which showed that RT
treatment increased the percentage of irregular nuclei,
characteristic of MC, when compared to the indivi-
dual treatments (Figure 4D), in agreement with direct
counting of irregular nuclei (Figure 4C). It is also im-
portant to notice that the percentage of large nuclei, a
feature of senescence induction, as previously described
for another glioma cell line [24], was increased by TMZ,
Rsv and RT treatments (Figure 4C and D).
Senescence mediates the chronic effects of RT treatment
To test the long term effect of RT treatment, which
more closely correlates with in vivo data [50], U87 cells
were treated for 48 h followed by Drug-Free Medium
(DFM). After fourteen days, Rsv and TMZ reduced the
number of colonies formed in 40% and 90%, respectively,
in relation to control (Figure 5A, left graph). Further-
more, colonies formed from Rsv or TMZ-treated cells
were much smaller when compared to untreated col-
onies. In RT-treated cells, in turn, no colonies were
observed, but only individual, senescent-like cells
(Figure 5A, right images).
TMZ induced senescence in around 50% of cells after
7 days in DFM, with the remaining cells showing normal
morphology (Figure 5B). These cells may be responsiblefor the colonies observed after TMZ treatment
(Figure 5A). RT induced a much higher proportion of
SA-beta-gal-positive cells than treatments alone in both
U87 (Figure 5B) and in primary GBM cells (Figure 5C).
SA-beta-gal-negative cells were not observed in RT
treated cultures (Figure 5B, insert), suggesting that Rsv
could reduce the appearance of TMZ resistance.
Discussion
Despite the use of a multimodal therapy, the prognosis
of GBM did not change in recent years [4]. Cytotoxicity
of clinically achievable serum levels of TMZ, which are
around 100 μM [51], was very small in the three glioma
cell lines and, furthermore, the primary glioma tumor
tested was resistant to TMZ, while Rsv was cytotoxic
alone and potentiated the effect of TMZ in these cells.
Therefore, drugs that enhance the effect of TMZ have
been actively studied [52,53] and may represent an alter-
native strategy for combined chemotherapy.
The effect of Rsv in increasing TMZ-induced toxicity
and autophagy occurred in all glioma cells tested, dem-
onstrating that it does not involve the p53 pathway,
since U251 and U138 cells are p53 mutant. The lack of
correlation between autophagy and cytotoxicity in three
GBM cell lines and the absence of reversion of the cyto-
toxicity by 3MA, despite a significant reduction in au-
tophagy, suggest that this is not a central mechanism in
the reduction in cell number. Indeed, autophagy induced
by co-treatment seems to be protective rather than cyto-
toxic. In U138 cells, which have high levels of MGMT
protein when compared to U251 and U87 cells, TMZ
did not trigger G2-cell cycle arrest, while U87 and U251
cells arrested at G2 with TMZ, also suggesting a
p53-independent arrest [5,54]. Furthermore, in agree-
ment with our data in U87 cells, Mhaidat et al. showed
that sensitivity of melanoma cells to TMZ was associ-
ated with MGMT status, G2 arrest and senescence entry,
while no apoptosis was induced [55].
Rsv induced a transitory S-phase arrest [21] and a
small increase in the phosphorylation of ATM, Chk2
and H2AX in U87 cells, while leading to a more
prolonged S-phase arrest in U251 and U138 cells.
Others also reported Rsv-induced S-phase arrest via
Figure 5 Cotreatment of Rsv and TMZ reduces clonogenic growth and induces senescence in glioma cells. U87 cells were treated with
Rsv 30 μM, TMZ 100 μM or RT for 48 h, followed by two washes for drug removal. Then, (A) cells were plated for clonogenic assay; left – number
of colonies after 14 days; right – representative images of colonies; scale bar: 100 μm; (B) cells were treated as above and plated for senescence
measurement; left – percentage of SA-beta-gal-positive cells; right – representative images of treated cells; insert = SA-beta-gal-negative cells in
TMZ-treated image. ** p<0.01 and *** p<0.001 in relation to control. (C) primary glioblastoma cells were treated as in above followed by growth
for 7 days in DFM and analyzed by SA-beta-gal assay.
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crease in nuclear size after 48 h of treatment in 32% of
cells, an indication of senescence induction, but after
7 days in DFM no senescent cells remained, suggesting
that the undamaged cells repopulated the well. On the
other hand, damage induced by TMZ seems to be more
long lasting, since 20% of large nuclei were observed
after 48 h and 50% of cells were SA-β-gal positive after
7 days in DFM, suggesting that even in the absence of
external TMZ, the damage induced in the 48 h oftreatment was maintained. Important to notice that the
combination of RT induced 25% of large and large
irregular nuclei at 48 h and 90% of SA-β-gal positive
after 7 days in DFM, suggesting that the presence of Rsv
potentiates the long lasting damage that leads to senes-
cence induced by TMZ.
Cell cycle arrest acts as a pro-survival mechanism,
since it gives extra time for DNA repair [5]. This is sup-
ported by the effect of an inhibitor of Chk2, which en-
hances the toxicity of TMZ through induction of MC
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abrogated by Rsv in U87 cells, without altering DNA
damage and ROS levels. However, RT treatment in-
creased the levels of gammaH2AX, pATM and pChk2 in
relation to the treatments alone. DNA damage links to
the mitotic machinery through phosphorylation of
CDC25 and Wee1 by Chks, inhibiting and activating
these enzymes, respectively. This leads to phosphoryl-
ation of tyrosine 15 and consequent inhibition of Cdk1
[60]. Experiments in Xenopus indicate that xChk1 phos-
phorylates xWee1 on Ser549, which corresponds to
Ser642 in hWee1 [60]. Phosphorylation of this site in
hWee1 was shown to be important for 14-3-3 binding
and activity, and Chk1 was among the kinases able to
phosphorylate this site in HELA cells [61]. TMZ induced
high levels of pWee1(S642), which were reduced by the
cotreatment with Rsv, leading to a reduction in pCdk1
after 48 h of treatment, suggesting a permissive status
for mitotic progression.
On the other hand, several molecular signs in RT
treated cells suggest G2 cell cycle arrest or early mitosis:
(1) high levels of pRb(S807/811), which is phos-
phorylated at the G1 to S transition [62] and
dephosphorylated at the M to G1 transition [63]; (2) low
levels of cyclin D1; (3) high levels of cyclin B1, which
needs to be degraded for the completion of mitosis [48];
and (4) low levels of histone H3 S10 phosphorylation,
which occurs in the early step of mitosis, being tightly
correlated with chromosome condensation during mi-
tosis [64]. This state of conflicted cell cycle signaling,
mainly accumulation of cyclin B [65] and decrease of
Cdk1(Y15) [66] was also observed in GBM cells treated
with radiation or doxorubicin and fluorouracil [67,68]
and was the underlying mechanism of MC induction. In-
deed, we observed an increase of cells with MC features
after RT treatment, which was not observed in the iso-
lated treatments.
In summary, considering the effect of Rsv on TMZ-
treated cells we noted that there was no effect on DNA
damage. At the early steps of DDR signaling, γH2AX,
pATM and pChk2, Rsv increased the levels induced by
TMZ. On the other hand, effectors of DDR signaling
that regulate the cell cycle were decreased by Rsv in
TMZ treated cells, mainly pWee1, pCdk1 and Histone
H3 phosphorylation, which are targets of Chk1/2. This
indicates that Rsv somehow potentiates the early steps
of DDR signaling while blocking the late stages, probably
at the level of Chk1/2, which may be responsible for the
lack of TMZ-induced arrest. Although the proportion of
cells with nuclear irregularities was relatively low (26%)
after 48 h, stretched out over the duration of a typical
TMZ therapy, i.e. several weeks, this mechanism, to-
gether with senescence induction, may be responsible
for the observed total reduction in clone formation after14 days. Indeed, the multiple mechanism of action of
TMZ plus Rsv cotreatment in glioma cells is thera-
peutically promising, since the induction of autophagy
[7], senescence and mitotic catastrophe, rather than high
level of apoptosis [69] seems to be important for the
mechanism of action of TMZ on GBM cells.
In conclusion, Rsv increases the toxicity of TMZ in
GBM cells through induction of multiple mechanisms,
mainly inhibition of TMZ-induced G2/M arrest followed
by induction of senescence and MC. The effects of the RT
combination are more clearly observed with long term
analysis, in which the combination totally abrogates
clonogenic growth. Thus, development of combinations of
drugs that induce multiple mechanisms of cell death and
growth arrest deserves attention and has a high potential
to be pre-clinically tested, due to the effectiveness to in-
duce the disruption of tumor cells, thus, reducing the pos-
sibility of resistance and recurrence.
Conclusions
In conclusion, our results showed that Rsv increases the
toxicity of TMZ in GBM cells mainly through the inhib-
ition of the G2/M arrest and induction of MC. Consider-
ing that almost 70% of GBM presented alterations on
p53 pathway [70], it is clinically relevant that a com-
bined therapy affects both populations, as was the case
of the combination of Rsv and TMZ. In the same way,
considering the primary therapeutic intervention to
GBM, which includes chemo and radiotherapy, the ob-
servation that TMZ sensitizes GBM cells to radiation
not through apoptosis, but through MC induction is also
noteworthy [32]. Thus, development of combinations of
drugs that induce MC, such as RT, deserves attention
and should be tested clinically, due to the effectiveness
of this mechanism to induce cell disruption.
Additional files
Additional file 1: Figure S1. Autophagy and toxicity in other glioma
cell. (a) U87, U138 or U251 cells were treated with Rsv 30 μM, TMZ
100 μM or RT for 48 h a, followed by cell number determination (upper
panel) and marking with AO followed by flow cytometry to determine
the percentage of AO-positive cells (lower panel); (b) primary
glioblastoma cells were treated as above and analyzed for cell number
and AO staining after 48 h Numbers in the quadrants refer to average of
events (black) or X-mean of AO red fluorescence intensity (red) ± SEM of
three independent experiments; * p<0.05, ** p<0.01.
Additional file 2: Figure S2. Apoptosis or ROS are not involved in RT
toxicity. U87 cells were treated with Rsv 30 μM, TMZ 100 μM or RT for
48 h. After this, cells were (a) stained with 6 μM PI, to evaluate the
membrane integrity and induction of necrosis - numbers indicate the
percentage of positively marked cells (ratio of PI labeled cells/total cells)
for at least 100 cells counted per treatment; scale bar: 100 μm; detail
shows the morphology of treated cells. (b) Cells were treated as in (a)
and marked with annexin V-FLUOS/PI and evaluated by flow cytometry.
Numbers in quadrants represents the percentage of cells ± SEM of three
independent experiments; (c) Cells were treated as in (a) and marked
with DCFH to measure reactive oxidative species followed by flow
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http://www.biomedcentral.com/1471-2407/13/147cytometry. Left -% in relation to control of DCFH intensity; right –
graphs of DCFH staining from Guava Software; n=2.
Additional file 3: Figure S3. Autophagy is not directly involved on
toxicity of the cotreatment of Rsv and TMZ. (a) Representative images of
U87 human GBM cells transfected with the plasmid pRGFP-LC3 and
treated with Rsv 30 μM, TMZ 100 μM or R30+T100 for 48 h; white arrows:
cytosolic green dots representing LC3-GFP marked autophagosomes;
scale bar: 10 μm; (b) percentage of cells that presented more than five
well-defined cytosolic green dots, for each treatment; a p<0.01 and b
p<0.001 in relation to control; (c) cells were treated as in (A), marked
with AO and the percentage of cells positively marked to acridine orange
(i.e. red marked cells) were evaluated by flow cytometry after 4, 24 and
48 h; a p<0.05 and b p<0.01 in relation to control.
Additional file 4: Figure S4. Rsv abrogates TMZ-induced arrest in G2/
Min U251 cells, while U138 is resistant to TMZ-induced arrest. Cell cycle
distribution of U251 and U138 cells treated with Rsv 30 μM, TMZ 100 μM
or RT, for 48 h. Representatives histograms are shown on the top of
figure of flow cytometry; numbers between the lines indicates the
percentage of cells in each phase of cell cycle, as indicated; cells were
treated as cited above, followed by fixation as described on material and
methods section, staining with 6 μM PI and flow cytometry to
determination of DNA content; * p<0.05; ** p<0.01.
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